A phase III trial showed that concurrent use of cobimetinib in combination with vemurafenib in patients with BRAF V600-mutant metastatic malignant melanoma results in prolongation of PFS, compared to vemurafenib monotherapy (9.9 months and 6.2 months, respectively) [36]. Here, BRAF is linked to metastatic melanoma.